OBJECTIVE： To provide reference for rational use of antiemetics in cancer patients. METHODS： The utilization of antiemetics in cancer outpatients and inpatients from 87 hospitals involved in “Hospital Prescription Analysis” project during 2012-2014 was analyzed statistically by time or by hospital category. RESULTS： 14 antiemetics were used in 87 hospitals during 2012-2014. The consumption sum and person number of antiemetics in cancer outpatients were 5 763 000 yuan and 34 000 persons [22 000 yuan/（year·hospital）， 133.1 person/（year·hospital） in average]； those of cancer inpatients were 61 711 000 yuan and 515 000 persons [256 000 yuan/（year·hospital）， 2 137.9 person/（year·hospital） in average]； those of outpatient were lower than those of inpatient. The ratio of consumption sum of antiemetics in cancer outpatients and inpatients were 5.2‰-34.0‰； the ratio of person number ranged 2.9％-10.9％. Those of inpatient were higher than those of outpatient； those of special hospital were higher than those of comprehensive hospital. Main drugs included ondansetron， tropisetron， metoclopramide and palonosetron. CONCLUSIONS： Antiemetics are frequently used in cancer patients， especially for 5-HT3 receptor antagonists and metoclopramide.